Chafic Karam, MD

Neurology

4.9 with 118 ratings

Sees patients age 18 and up

Chafic Karam, MD

Neurology

4.9 with 118 ratings

Sees patients age 18 and up

Professor of Clinical Neurology
Dr. Karam is a Penn Medicine physician.

Call 800-789-7366 Request Appointment

Amyloid Neuropathy
Autoimmune Neuropathy
Charcot Marie Tooth Disease (CMT)
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Electrodiagnostic Medicine
Electromyography
Guillain-Barré Syndrome (GBS)
Nerve Conduction Studies
Neuromuscular Therapy
Peripheral Neuropathy

Programs and Centers

Penn Medicine's programs and centers combine doctors from many disciplines to coordinate care from start to finish. Dr. Karam is part of these programs:

Penn Amyloidosis Program
Penn Neuromuscular Disorders Program

Board Certification

Neurology, 2011
Neuromuscular Medicine, 2012

Education and Training

Medical School: Saint Joseph's University Medical School
Residency: Hotel Dieu de France; Mount Sinai Beth Israel; Brigham and Women's Hospital; Mayo Clinic

Primary Location

Penn Neuroscience Center - Neurology

Perelman Center for Advanced Medicine
South Pavilion, 2nd Floor
3400 Civic Center Boulevard
Philadelphia, PA 19104

Map Call 800-789-7366

View details

Penn Medicine Hospital Privileges

Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
Pennsylvania Hospital: Has privileges to treat patients in the hospital.

Overall Ratings

out of 5 ; Ratings;

The Patient Satisfaction Rating is an average of all responses to the care provider related question shown above from our internal platform, PMX Feedback. Responses are measured on a scale of 1 to 5 with 5 being the best score. Scores reflect either the most recent 12 months of surveys or the most recent 30 surveys overall. Data is updated monthly and comments remain on the profile for 12 months.

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Patients that are treated in outpatient or hospital environments may receive different surveys.

Please contact the practice and/or the member services department of your insurance company for specific details before receiving services. Providers may participate in some, but not all, products offered by a health plan; providers may also accept plans at some practice locations but not others.

Aetna US Healthcare
Centivo Health Plan
Cigna
Cigna HealthSpring
Clover Health Plan
Devon Health Services (Americare)
Gateway Health Plan
Geisinger Health Plan
Geisinger Medicaid
Global Medical Management
HealthAmerica / HealthAssurance, a Coventry Plan
HealthPartners
HealthPartners Medicare
HealthSmart
Highmark Blue Shield
Homestead Smart Health Plans/Claim Watcher
Horizon Blue Cross Blue Shield of New Jersey
Humana / Choicecare
Humana / Medicare

Imagine Health 360
Independence Blue Cross (Keystone East)
Keystone First
Keystone First Medicare
NJ Medicaid
NJ Qualcare
Oscar Health Plan of PA
Oxford Health Plan
PA Health and Wellness (Centene) Medicare
PA Medicaid
PA Medicare
Provider Partners Health Plan
Rail Road Medicare / Palmetto GBA
Tricare
United Healthcare
UnitedHealthcare Community Plan
US Family Health Plan
Veterans Choice Program

Selected Publications

Morganroth J, Karam C.: Anti-Myelin-Associated Glycoprotein Neuropathy: Recent Developments Neurol Clin Pract. : 2025.

Qarni TN, Jones FJS, Drachman B, Khella S, Pieretti J, Bustamante NS, Karam C.: Treatment characteristics of patients with hereditary transthyretin amyloidosis: a cohort study Orphanet J Rare Dis. : 2024 .

Bhatt K, Delgado DH, Khella S, Bumma N, Karam C, Keller A, Rosen AM, Bozas A, Shea A, Towne MC, Polfus LM, Kaeser GE, Sanjurjo V, Shah KB.: Hereditary Transthyretin Amyloidosis in Patients Referred to a Genetic Testing Program. J Am Heart Assoc. 2024 Nov 22:e033770. : 2024.

Karam C, Moffit C, Summers C, Merkel MP, Kochman FM, Weijers L, Puls M, Schurer M, Jones E, Mason N, Finkel M, Schmitt P, Hanna M.: The journey to diagnosis of wild-type transthyretin-mediated (ATTRwt) amyloidosis: a path with multisystem involvement. Orphanet J Rare Dis. : 2024.

Jones FJS, Zager E, Karam C.: Clinical Reasoning: A 61-Year-Old Man With Progressive Right Leg Numbness and Weakness. Neurology. 2024 Oct 22;103(8):e209900 : 2024.

Qarni T, Moshe-Lilie O, Kaku MC, Karam C.: Hereditary Transthyretin Amyloidosis Polyneuropathy Semin Neurol. : 2024.

Suhr, O. B., Grogan, M., Silva, A. M. da, Karam, C., Garcia-Pavia, P., Drachman, B., … Kinney, G. G.: PRX004 in variant amyloid transthyretin (ATTRv) amyloidosis: results of a phase 1, open-label, dose-escalation study. Amyloid. 2024 Oct 29:1-8. : 2024.

Jones FJS, Cohen AD, Karam C.: Clinical Reasoning: A 49-Year-Old Man With Progressive Numbness, Gait Instability, and Tremors Neurology. 2024 Oct 8;103(7):e209879. : 2024.

Berth SH, Vo L, Kwon DH, Grider T, Damayanti YS, Kosmanopoulos G, Fox A, Lau AR, Carr P, Donohue JK, Hoke M, Thomas S, Karam C, Fay AJ, Meltzer E, Crawford TO, Gaudet R, Shy ME, Hellmich UA, Lee SY, Sumner CJ, McCray BA.: Combined clinical, structural, and cellular studies discriminate pathogenic and benign TRPV4 variants. Brain. : 2024.

Jones FJS, Singer M, Zager E, Karam C.: Mononeuropathy Due to Inflammatory Pseudotumor of Nerve Neurology. : 2024.

View all publications

Academic Contact Information

3400 Spruce St., 3 West Gates
Philadelphia, PA 19104
Phone: 215-615-3751
Patient appointments: 800-789-7366

American Academy of Neurology, International
American Association of Neuromuscular & Electrodiagnostic Medicine, International
American Association of Neuromuscular & Electrodiagnostic Medicine, National
Chairperson, adjudication committee charter for hereditary transthyretin amyloidosis with polyneuropathy (hattr-pn), International
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Confirmation Committee, International
European Science Foundation, International
GBS/CIDP Foundation Global Medical Advisory Board, International
Muscle Study Group, International
Myasthenia Gravis Foundation of America, National